Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Etsuko Usuki"'
Publikováno v:
Drug-Drug Interactions ISBN: 9780429131967
Victims are those drugs whose clearance is predominantly determined by a single route of elimination, such as metabolism by a single cytochrome P450 (CYP) enzyme. This chapter focuses on in vitro reaction phenotyping and CYP inhibition. A wide range
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::619c8ec61412d5171b542eaf065ff119
https://doi.org/10.1201/9780429131967-7
https://doi.org/10.1201/9780429131967-7
Autor:
Brian W. Ogilvie, Andrew Parkinson, Fred Tonelli, Etsuko Usuki, Anne Schmitt-Hoffmann, Dawn Baumgardner, Jennifer Skibbe, Mark D. Johnson, Gary Eichenbaum, Jeff Holsapple
Publikováno v:
Journal of Pharmaceutical Sciences. 101:1242-1252
An approach was developed that uses enzyme inhibitors to support the assessment of the pathways that are responsible for the conversion of intravenously administered ester and amide prodrugs in different biological matrices. The methodology was appli
Autor:
Dan Brobst, Brandy L. Paris, Florence Ndikum-Moffor, Etsuko Usuki, Andrew Parkinson, Jennifer Skibbe, Ivan King, Brian W. Ogilvie, Alaa-Eldin F Nassar, Lois J. Haupt, Rebecca Campbell
Publikováno v:
Drug Metabolism and Disposition. 37:1922-1930
Laromustine (VNP40101M, also known as Cloretazine) is a novel sulfonylhydrazine alkylating (anticancer) agent. Laromustine generates two types of reactive intermediates: 90CE and methylisocyanate. When incubated with rat, dog, monkey, and human liver
Autor:
Oliver T. Parkinson, Mary F. Paine, James L. Allen, Janelle Y. Saulter, Michael Hall, David W. Boykin, James Edwin Hall, Greg J. Loewen, Richard R. Tidwell, Chad E. Stephens, Etsuko Usuki, Darryl C. Zeldin, Yen Ling Cheung, Arlene S. Bridges, Andrew Parkinson, Michael Zhuo Wang
Publikováno v:
Drug Metabolism and Disposition. 34:1985-1994
DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime] is biotransformed to the potent antiparasitic diamidine DB75 [2,5-bis(4-amidinophenyl) furan] by sequential oxidative O-demethylation and reductive N-dehydroxylation reactions. Previous work
Autor:
Cornelis J. Van der Schyf, Kay Castagnoli, Jeffrey R. Bloomquist, Etsuko Usuki, Ethan R. Freeborn, Neal Castagnoli
Publikováno v:
Neurotoxicity Research. 4:51-58
The neuroleptic agent haloperidol (HP) and its tetrahydropyridinyl dehydration product HPTP are biotransformed by humans, baboons and rodents to the HP pyridinium (HPP(+)) and reduced HP pyridinium (RHPP(+)) species, potential neurotoxic metabolites
Autor:
Gilles L. Fraser, Kathryn M. Avent, Richard R. Riker, Susan Pond, Cornelis J. Van der Schyf, Etsuko Usuki
Publikováno v:
Life Sciences. 61:2383-2390
The metabolism of haloperidol (HP) to the potentially neurotoxic pyridinium species, HPP+ and RHPP+, has been demonstrated in humans. In vitro studies in microsomes harvested from various animal species indicate that the tetrahydropyridines, HPTP and
Publikováno v:
Life Sciences. 57:2439-2446
The levels of haloperidol (HP) and its pyridinium metabolite HPP+ were estimated in plasma and brain tissues of rats treated i.p. with HP (10 mg/kg). HP and HPP+ levels in plasma decreased linearly during the 0-3 hour period following drug administra
Autor:
Andrew Parkinson, L M Kao, James B Parker, Angelique Leone, Kelley Michael F, Alex Nie, Mark D. Johnson, Michael K. McMillian, Etsuko Usuki, Peter Lord
Publikováno v:
Chemical research in toxicology. 20(4)
Felbamate is an antiepileptic drug that is associated with minimal toxicity in preclinical species such as rat and dog but has an unacceptable incidence of serious idiosyncratic reactions in man. Idiosyncratic reactions account for over half of toxic
Publikováno v:
Drug metabolism reviews. 30(4)
(1998). Metabolism of Haloperidol and Its Tetrahydropyridine Dehydration Product HPTP. Drug Metabolism Reviews: Vol. 30, No. 4, pp. 809-826.